NZSE:ATMFood
Does New A1 Protein‑Free Formula Data Change The Bull Case For a2 Milk (NZSE:ATM)?
The a2 Milk Company recently presented new clinical and preclinical data at NUTRITION 2026 showing its A1 protein‑free infant formula supported normal growth and met U.S. FDA safety criteria through 16 weeks of age.
Exploratory findings indicating greater gains in infant length and weight, plus signs of improved protein utilization and gut health, underscore how a2 Milk is using science to differentiate its formula offerings.
We’ll now examine how evidence that A1 protein‑free formula...